Strict monitoring and surveillance systems for the safety of all vaccines, including those for COVID-19, are in place during vaccine trials as well as once vaccines are rolled out more widely. Adele Baleta takes a look at how vaccine-related adverse events are monitored in South Africa.
South Africa is likely headed for a third wave of COVID-19 infections, experts warn. With no windfall of vaccines in sight, many people at high risk of COVID-19 will remain unvaccinated. Now some doctors and medical ethicists are asking: Is a safe vaccine that could possibly protect them better than nothing?
Some foreign nationals in South Africa, their community leaders, human rights lawyers and activists are concerned that their health needs are falling through the cracks. This was compounded during lockdown with some foreign nationals claiming they were refused healthcare and others now concerned they will be excluded from the vaccine rollout. Luvuyo Mehlwana reports.
The national budget tabled this week shows that planned spending on public health is reduced by a massive R50.3 billion over the next three years. We cannot accept a vaccine versus health system trade-off. Government must both expedite the procurement of vaccines and ensure that provinces have the staff and other capabilities to rapidly roll them out and to maintain and improve the quality of healthcare services, argue writers from SECTION27.
Provinces manage the day-to-day running of the public healthcare system in South Africa and provinces will be responsible for the massive logistical effort of getting COVID-19 vaccines from fridges and depots into people’s arms. Elri Voigt has been keeping track of the nine provinces’ plans.
The shortcomings of healthcare services in the rural Eastern Cape is well documented. Now, with provinces gearing up for the COVID-19 vaccine rollout, Luvuyo Mehlwana asked local health activists and government leaders about the rollout plan for rural communities in the province.
Government deserves criticism for various aspects of its COVID-19 response, but some social media criticism following Sunday’s announcement that the Oxford University/AstraZeneca vaccine has little or no efficacy in preventing mild-to-moderate disease caused by the 501Y.V2 variant has been unfair, writes Marcus Low.
While local experts generally welcome the order in which vaccines will be provided to different categories of people in South Africa, they are concerned that some practical nuances are unclear. Elna Schütz reports.